Linden Thomas Advisory Services LLC Has $1.11 Million Holdings in West Pharmaceutical Services, Inc. $WST

Linden Thomas Advisory Services LLC lifted its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 2.8% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,072 shares of the medical instruments supplier’s stock after acquiring an additional 140 shares during the quarter. Linden Thomas Advisory Services LLC’s holdings in West Pharmaceutical Services were worth $1,110,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Zions Bancorporation National Association UT purchased a new stake in shares of West Pharmaceutical Services in the first quarter valued at $25,000. Quarry LP purchased a new stake in West Pharmaceutical Services in the 1st quarter worth about $27,000. First Horizon Advisors Inc. boosted its position in West Pharmaceutical Services by 85.0% during the 1st quarter. First Horizon Advisors Inc. now owns 185 shares of the medical instruments supplier’s stock worth $41,000 after acquiring an additional 85 shares during the period. CVA Family Office LLC grew its stake in West Pharmaceutical Services by 573.3% during the 2nd quarter. CVA Family Office LLC now owns 202 shares of the medical instruments supplier’s stock valued at $44,000 after acquiring an additional 172 shares in the last quarter. Finally, Cromwell Holdings LLC increased its holdings in shares of West Pharmaceutical Services by 587.5% in the 2nd quarter. Cromwell Holdings LLC now owns 220 shares of the medical instruments supplier’s stock valued at $48,000 after purchasing an additional 188 shares during the period. 93.90% of the stock is currently owned by hedge funds and other institutional investors.

West Pharmaceutical Services Stock Performance

Shares of WST opened at $298.13 on Monday. The firm has a market cap of $21.45 billion, a price-to-earnings ratio of 44.17, a price-to-earnings-growth ratio of 4.40 and a beta of 1.07. The company’s fifty day moving average is $259.30 and its 200-day moving average is $234.65. The company has a quick ratio of 2.18, a current ratio of 2.87 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a 12 month low of $187.43 and a 12 month high of $348.90.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings data on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.29. The business had revenue of $804.60 million during the quarter, compared to analyst estimates of $788.42 million. West Pharmaceutical Services had a net margin of 16.29% and a return on equity of 18.16%. West Pharmaceutical Services’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.85 EPS. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. Equities analysts expect that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current fiscal year.

Analyst Ratings Changes

WST has been the subject of several research reports. Zacks Research cut shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 23rd. Weiss Ratings reiterated a “hold (c)” rating on shares of West Pharmaceutical Services in a research report on Tuesday, October 14th. Rothschild Redb raised shares of West Pharmaceutical Services to a “strong-buy” rating in a research note on Monday, September 15th. Wall Street Zen raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating in a research note on Saturday, July 26th. Finally, Deutsche Bank Aktiengesellschaft set a $345.00 price objective on West Pharmaceutical Services and gave the company a “buy” rating in a research report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $343.56.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.